Impact of traditional East Asian medicine as an add-on therapy on survival and recurrence after surgery for breast cancer: A systematic review and meta-analysis

Background: Breast cancer is the most common cancer in women. Patients with cancer increasingly incorporate complementary and alternative medicines, including traditional East Asian medicine (TEAM), for cancer prevention and treatment. This review aimed to determine the effectiveness and safety of T...

Full description

Bibliographic Details
Main Authors: Jee-Hyun Yoon, Eun Hye Kim, Su Bin Park, Hayun Jin, Seong Woo Yoon
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-04-01
Series:Frontiers in Pharmacology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2023.1125373/full
_version_ 1797853001082208256
author Jee-Hyun Yoon
Eun Hye Kim
Su Bin Park
Hayun Jin
Seong Woo Yoon
author_facet Jee-Hyun Yoon
Eun Hye Kim
Su Bin Park
Hayun Jin
Seong Woo Yoon
author_sort Jee-Hyun Yoon
collection DOAJ
description Background: Breast cancer is the most common cancer in women. Patients with cancer increasingly incorporate complementary and alternative medicines, including traditional East Asian medicine (TEAM), for cancer prevention and treatment. This review aimed to determine the effectiveness and safety of TEAM for survival and recurrence after surgery in patients with breast cancer.Methods: We searched nine electronic databases up to 25 August 2022, for randomized controlled trials (RCTs) of TEAM to prevent the recurrence of breast cancer in female patients after mastectomy or breast-conserving surgery. The primary outcome was 5-year disease-free survival (DFS), and secondary outcomes were 5-year overall survival, locoregional and distant recurrence rates, and toxicity. This study adhered to the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) was used to evaluate the quality of evidence.Results: From 368 citations, data from nine studies reporting on a total of 1240 patients were included in the systematic review, and eight studies were deemed suitable for the meta-analysis. TEAM combined with adjuvant chemotherapy showed a significant improvement in DFS (odds ratio [OR] 0.42%, 95% confidence interval [CI] 0.28 to 0.61, p < 0.00001) and overall survival (OR 0.44%, 95% CI 0.27 to 0.73, p = 0.001) compared to adjuvant chemotherapy alone. The reduction in the rate of total recurrence was favorable for TEAM combined with adjuvant chemotherapy compared to adjuvant chemotherapy alone (Risk ratio 0.49%, 95% CI 0.35 to 0.70; p < 0.0001). TEAM after adjuvant chemotherapy showed a significant advantage in DFS compared to no TEAM (OR 0.61%, 95% CI 0.41 to 0.92, p = 0.02). No severe adverse events related to TEAM were reported. The overall certainty of the evidence for DFS, overall survival, and the total recurrence rate were moderate when postoperative breast cancer patients used TEAM combined with adjuvant chemotherapy.Conclusion: Moderate-quality evidence suggests TEAM as an add-on therapy to adjuvant chemotherapy. TEAM may have the potential to improve long-term survival and prevent postoperative recurrence in patients with breast cancer. In future, more rigorous RCTs should be conducted to confirm these findings.
first_indexed 2024-04-09T19:42:20Z
format Article
id doaj.art-a9eb64d2e5d44e75b3dd492010acefb2
institution Directory Open Access Journal
issn 1663-9812
language English
last_indexed 2024-04-09T19:42:20Z
publishDate 2023-04-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Pharmacology
spelling doaj.art-a9eb64d2e5d44e75b3dd492010acefb22023-04-04T04:28:33ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122023-04-011410.3389/fphar.2023.11253731125373Impact of traditional East Asian medicine as an add-on therapy on survival and recurrence after surgery for breast cancer: A systematic review and meta-analysisJee-Hyun YoonEun Hye KimSu Bin ParkHayun JinSeong Woo YoonBackground: Breast cancer is the most common cancer in women. Patients with cancer increasingly incorporate complementary and alternative medicines, including traditional East Asian medicine (TEAM), for cancer prevention and treatment. This review aimed to determine the effectiveness and safety of TEAM for survival and recurrence after surgery in patients with breast cancer.Methods: We searched nine electronic databases up to 25 August 2022, for randomized controlled trials (RCTs) of TEAM to prevent the recurrence of breast cancer in female patients after mastectomy or breast-conserving surgery. The primary outcome was 5-year disease-free survival (DFS), and secondary outcomes were 5-year overall survival, locoregional and distant recurrence rates, and toxicity. This study adhered to the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) was used to evaluate the quality of evidence.Results: From 368 citations, data from nine studies reporting on a total of 1240 patients were included in the systematic review, and eight studies were deemed suitable for the meta-analysis. TEAM combined with adjuvant chemotherapy showed a significant improvement in DFS (odds ratio [OR] 0.42%, 95% confidence interval [CI] 0.28 to 0.61, p < 0.00001) and overall survival (OR 0.44%, 95% CI 0.27 to 0.73, p = 0.001) compared to adjuvant chemotherapy alone. The reduction in the rate of total recurrence was favorable for TEAM combined with adjuvant chemotherapy compared to adjuvant chemotherapy alone (Risk ratio 0.49%, 95% CI 0.35 to 0.70; p < 0.0001). TEAM after adjuvant chemotherapy showed a significant advantage in DFS compared to no TEAM (OR 0.61%, 95% CI 0.41 to 0.92, p = 0.02). No severe adverse events related to TEAM were reported. The overall certainty of the evidence for DFS, overall survival, and the total recurrence rate were moderate when postoperative breast cancer patients used TEAM combined with adjuvant chemotherapy.Conclusion: Moderate-quality evidence suggests TEAM as an add-on therapy to adjuvant chemotherapy. TEAM may have the potential to improve long-term survival and prevent postoperative recurrence in patients with breast cancer. In future, more rigorous RCTs should be conducted to confirm these findings.https://www.frontiersin.org/articles/10.3389/fphar.2023.1125373/fullbreast cancertraditional East Asian medicinesurvivalrecurrencemeta-analysissystematic review
spellingShingle Jee-Hyun Yoon
Eun Hye Kim
Su Bin Park
Hayun Jin
Seong Woo Yoon
Impact of traditional East Asian medicine as an add-on therapy on survival and recurrence after surgery for breast cancer: A systematic review and meta-analysis
Frontiers in Pharmacology
breast cancer
traditional East Asian medicine
survival
recurrence
meta-analysis
systematic review
title Impact of traditional East Asian medicine as an add-on therapy on survival and recurrence after surgery for breast cancer: A systematic review and meta-analysis
title_full Impact of traditional East Asian medicine as an add-on therapy on survival and recurrence after surgery for breast cancer: A systematic review and meta-analysis
title_fullStr Impact of traditional East Asian medicine as an add-on therapy on survival and recurrence after surgery for breast cancer: A systematic review and meta-analysis
title_full_unstemmed Impact of traditional East Asian medicine as an add-on therapy on survival and recurrence after surgery for breast cancer: A systematic review and meta-analysis
title_short Impact of traditional East Asian medicine as an add-on therapy on survival and recurrence after surgery for breast cancer: A systematic review and meta-analysis
title_sort impact of traditional east asian medicine as an add on therapy on survival and recurrence after surgery for breast cancer a systematic review and meta analysis
topic breast cancer
traditional East Asian medicine
survival
recurrence
meta-analysis
systematic review
url https://www.frontiersin.org/articles/10.3389/fphar.2023.1125373/full
work_keys_str_mv AT jeehyunyoon impactoftraditionaleastasianmedicineasanaddontherapyonsurvivalandrecurrenceaftersurgeryforbreastcancerasystematicreviewandmetaanalysis
AT eunhyekim impactoftraditionaleastasianmedicineasanaddontherapyonsurvivalandrecurrenceaftersurgeryforbreastcancerasystematicreviewandmetaanalysis
AT subinpark impactoftraditionaleastasianmedicineasanaddontherapyonsurvivalandrecurrenceaftersurgeryforbreastcancerasystematicreviewandmetaanalysis
AT hayunjin impactoftraditionaleastasianmedicineasanaddontherapyonsurvivalandrecurrenceaftersurgeryforbreastcancerasystematicreviewandmetaanalysis
AT seongwooyoon impactoftraditionaleastasianmedicineasanaddontherapyonsurvivalandrecurrenceaftersurgeryforbreastcancerasystematicreviewandmetaanalysis